Cystic Fibrosis drugs to cost €400 million over ten years
The HSE and the drug’s maker Vertex have reached a deal in principle on providing the drugs Orkambi and Kalydeco to CF patients
Independent journalism every day
With digital access you can read The Business Post whenever, wherever, and however you want.
- Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
- Breaking news, comment and analysis from the best Business Post writers seven days a week.
- Live blogs of major news events
- Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
- Access to The Business Post's extensive archive